Scholarlink

Background <p>Functional mitral regurgitation (FMR) carries poor prognosis, and optimal management remains debated. Mitral Transcatheter Edge-to-Edge Repair (MTEER) is an alternative to surgical repair (SMVR) or optimized medical therapy (OMT), but long-term outcomes are uncertain.</p> Methods <p>PubMed, Embase, Scopus, and the Cochrane Library were searched for studies reporting Kaplan–Meier curves of MTEER, SMVR, or OMT in FMR. Individual patient data (IPD) were reconstructed using the Liu method with accuracy checks. Pooled IPD were analyzed with Cox and time-varying Cox models, landmark, time-restricted, and restricted mean survival time analyses.</p> Results <p>Sixteen studies (<i>n</i> = 4,570) were included. Patients undergoing MTEER were older and higher risk, with greater prevalence of atrial fibrillation, prior myocardial infarction, chronic kidney disease, higher EuroSCORE, and more frequent NYHA class ≥ III compared with SMVR. Over up to 60 months, both MTEER (HR: 0.65; 95% CI: 0.57–0.75; <i>p</i> &lt; 0.001) and SMVR (HR: 0.39; 95% CI: 0.33–0.46; <i>p</i> &lt; 0.001) significantly reduced all-cause mortality versus OMT, whereas MTEER carried higher mortality risk than SMVR (HR: 1.68; 95% CI: 1.43–1.97; <i>p</i> &lt; 0.001). MTEER was less effective than SMVR in reducing recurrent MR &gt; 2 (HR: 3.31; 95% CI: 1.62–6.75; <i>p</i> &lt; 0.001) and reoperation (HR: 4.62; 95% CI: 2.22–9.61; <i>p</i> &lt; 0.001). In contrast, MTEER reduced hospitalization risk by 30% compared to OMT (HR: 0.70; 95% CI: 0.64–0.77; <i>p</i> &lt; 0.001) and decreased MACE by 21% (HR: 0.79; 95% CI: 0.73–0.84; <i>p</i> &lt; 0.001).</p> Conclusions <p>MTEER improves survival and reduces hospitalization and MACE compared with OMT but is less durable than SMVR, with higher risks of recurrent MR, reoperation, and late mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Functional mitral valve regurgitation outcomes by treatment modality: a systematic review and meta-analysis of reconstructed survival data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Parham Dastjerdi,
  • Kiarash Tavakoli,
  • Roozbeh Narimani-Javid,
  • Nazanin Anaraki,
  • Hedieh Shayesteh,
  • Negin Sadat Hosseini Mohammadi,
  • Saghar Momeni,
  • Reza Nikfar,
  • Soheil Rahmati,
  • Amr Mohsen,
  • Kaveh Hosseini,
  • Hamidreza Soleimani

摘要

Background

Functional mitral regurgitation (FMR) carries poor prognosis, and optimal management remains debated. Mitral Transcatheter Edge-to-Edge Repair (MTEER) is an alternative to surgical repair (SMVR) or optimized medical therapy (OMT), but long-term outcomes are uncertain.

Methods

PubMed, Embase, Scopus, and the Cochrane Library were searched for studies reporting Kaplan–Meier curves of MTEER, SMVR, or OMT in FMR. Individual patient data (IPD) were reconstructed using the Liu method with accuracy checks. Pooled IPD were analyzed with Cox and time-varying Cox models, landmark, time-restricted, and restricted mean survival time analyses.

Results

Sixteen studies (n = 4,570) were included. Patients undergoing MTEER were older and higher risk, with greater prevalence of atrial fibrillation, prior myocardial infarction, chronic kidney disease, higher EuroSCORE, and more frequent NYHA class ≥ III compared with SMVR. Over up to 60 months, both MTEER (HR: 0.65; 95% CI: 0.57–0.75; p < 0.001) and SMVR (HR: 0.39; 95% CI: 0.33–0.46; p < 0.001) significantly reduced all-cause mortality versus OMT, whereas MTEER carried higher mortality risk than SMVR (HR: 1.68; 95% CI: 1.43–1.97; p < 0.001). MTEER was less effective than SMVR in reducing recurrent MR > 2 (HR: 3.31; 95% CI: 1.62–6.75; p < 0.001) and reoperation (HR: 4.62; 95% CI: 2.22–9.61; p < 0.001). In contrast, MTEER reduced hospitalization risk by 30% compared to OMT (HR: 0.70; 95% CI: 0.64–0.77; p < 0.001) and decreased MACE by 21% (HR: 0.79; 95% CI: 0.73–0.84; p < 0.001).

Conclusions

MTEER improves survival and reduces hospitalization and MACE compared with OMT but is less durable than SMVR, with higher risks of recurrent MR, reoperation, and late mortality.